The University of Chicago Header Logo

Connection

Jeffrey Matthews to Maytansine

Back to Details
This is a "connection" page, showing publications Jeffrey Matthews has written about Maytansine.
Jeffrey Matthews
Connection Strength
0.045
Maytansine
  1. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. Nat Commun. 2021 11 05; 12(1):6428.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.